Key Highlights
- B. Riley reduced Oklo’s price target to $92 from $129 while maintaining Buy rating
- Craig-Hallum adjusted its forecast to $71 from $87, keeping Hold rating due to expanding capital requirements
- Needham revised its projection to $73 from $135 while retaining Buy rating, suggesting approximately 20% potential gain
- CEO Jacob Dewitte and CFO Richard Bealmear each divested approximately 72,000 shares at $60 per share on March 13; total insider sales reached ~$170M across 90 days
- Oklo’s Atomic Alchemy division secured DOE Nuclear Safety Design Agreement and NRC materials license approvals
The past six months have proven challenging for Oklo’s stock performance. The nuclear energy startup, currently trading around $60.76, has declined 42% during this timeframe and remains significantly below its 52-week peak of $193.84.
Multiple Wall Street firms adjusted their price projections downward this week after reviewing the company’s Q4 2025 earnings release. The revised targets reflect changing expectations, though most analysts continue supporting the company’s long-term prospects.
B. Riley revised its forecast to $92 from $129 while maintaining its Buy recommendation. The firm highlighted meaningful operational achievements: DOE clearances for the Aurora facility at Idaho National Laboratory, a prepayment arrangement with Meta covering up to 1.2 gigawatts in Ohio, initial fuel facility development, and regulatory achievements for its Atomic Alchemy isotope division.
Needham retained its Buy stance while substantially lowering its target to $73 from $135. The updated projection continues to suggest roughly 20% appreciation potential from present levels, and Wall Street’s consensus target remains near $94.80 with a “Moderate Buy” rating.
Craig-Hallum maintained its Hold position and decreased its target to $71 from $87. The firm updated its financial models to reflect elevated operating costs, increased capital expenditures, and adjusted timeline assumptions regarding future funding requirements. The firm excluded anticipated 2026 isotope revenue — projected below $5 million — from its calculations pending additional information.
Rising Capital Requirements and Executive Sales Create Headwinds
Oklo concluded Q4 2025 with $1.4 billion in available cash. Following the quarter’s end, the company secured another $1.2 billion in funding. Management projects operating cash consumption between $80 million and $100 million for 2026, with investing cash usage ranging from $350 million to $450 million.
Despite substantial cash reserves, the company recorded an EBITDA deficit of $97 million during the trailing twelve months and a full-year 2025 operating shortfall of $139.3 million. Wall Street forecasts indicate profitability remains beyond the current year’s horizon.
Executive stock transactions added to market concerns. CEO Jacob Dewitte divested approximately 72,960 shares on March 13 at $60 per share, totaling roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares the same day at an identical price, amounting to around $4.33 million. During the preceding 90-day period, company insiders offloaded approximately 2.07 million shares valued at roughly $170 million collectively. Insider ownership remains at 18.9% of outstanding shares.
Regulatory Milestones Provide Forward Momentum
Oklo has achieved meaningful regulatory progress. The company’s Atomic Alchemy subsidiary obtained a DOE Nuclear Safety Design Agreement covering its Groves isotopes test reactor. The division also secured an NRC materials and isotope license — marking the first NRC authorization Oklo has obtained via an acquired entity.
The Aurora reactor received initial design clearance from the Department of Energy, representing a crucial milestone for advancing the 1.2-gigawatt supply arrangement with Meta, scheduled for delivery by 2034.
William Blair maintained an Outperform rating. Cantor Fitzgerald continued its Overweight stance with a $122 projection. Barclays holds an Overweight rating with an $82 target. Bank of America maintains a Buy rating with a $127 price objective.
Oklo’s 50-day moving average currently sits at $75.08 while its 200-day moving average reaches $95.27. The company’s market capitalization stands at approximately $9.49 billion.
